Literature DB >> 20188145

T regulatory cells, the evolution of targeted immunotherapy.

S Nizar1, B Meyer, C Galustian, D Kumar, A Dalgleish.   

Abstract

T regulatory cells are able to suppress anti-tumour immunity in pre-clinical models and in patients. This review highlights the important discoveries in Treg immunology critical to the evolution of targeted immunotherapy. We also describe the therapeutic applications that are currently being assessed and their future potential. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20188145     DOI： 10.1016/j.bbcan.2010.02.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  14 in total

Review 1.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 2.  Regulatory T cells in the immunotherapy of melanoma.

Authors:  Zhengxiao Ouyang; Hongwei Wu; Linqin Li; Yi Luo; Xianan Li; Gang Huang
Journal:  Tumour Biol       Date:  2015-10-30

3.  CD4+ CD25- FoxP3+ regulatory cells are the predominant responding regulatory T cells after human rotavirus infection or vaccination in gnotobiotic pigs.

Authors:  Ke Wen; Guohua Li; Xingdong Yang; Tammy Bui; Muqun Bai; Fangning Liu; Jacob Kocher; Lijuan Yuan
Journal:  Immunology       Date:  2012-10       Impact factor: 7.397

4.  High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs.

Authors:  Ke Wen; Guohua Li; Tammy Bui; Fangning Liu; Yanru Li; Jacob Kocher; Lin Lin; Xingdong Yang; Lijuan Yuan
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641

5.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Authors:  Arnaud Pommier; Alexandra Audemard; Aurélie Durand; Renée Lengagne; Arnaud Delpoux; Bruno Martin; Laetitia Douguet; Armelle Le Campion; Masashi Kato; Marie-Françoise Avril; Cédric Auffray; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

6.  Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.

Authors:  C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour
Journal:  Cancer Microenviron       Date:  2012-10-27

Review 7.  Cancer-associated fibroblasts as targets for immunotherapy.

Authors:  Sunitha Kakarla; Xiao-Tong Song; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2012-11       Impact factor: 4.196

8.  Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity.

Authors:  Shuang Zhou; Long Chen; Jie Qin; Rilun Li; Huihong Tao; Zhiwei Zhen; Haixia Chen; Guolin Chen; Yaoqin Yang; Binbin Liu; Zhenjue She; Cuiping Zhong; Chunmin Liang
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

9.  Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy.

Authors:  Duane Moogk; Ines Pires da Silva; Michelle W Ma; Erica B Friedman; Eleazar Vega-Saenz de Miera; Farbod Darvishian; Patrick Scanlon; Arianne Perez-Garcia; Anna C Pavlick; Nina Bhardwaj; Paul J Christos; Iman Osman; Michelle Krogsgaard
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

10.  A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.

Authors:  Jinxu Fang; Biliang Hu; Si Li; Chupei Zhang; Yarong Liu; Pin Wang
Journal:  Mol Ther Oncolytics       Date:  2016-03-16       Impact factor: 7.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.